<i>In silico</i>and<i>in vitro</i>evaluation of exonic and intronic off-target effects form a critical element of therapeutic ASO gapmer optimization
Piotr J. Kamola(GlaxoSmithKline (United Kingdom)), Joel D. Parry(Age UK), Mark R. Edbrooke(GlaxoSmithKline (United Kingdom)), Nigel J. Gooderham(Imperial College London), Aliza A. Panjwani(GlaxoSmithKline (United Kingdom)), Kenneth L. Clark(GlaxoSmithKline (United Kingdom)), Paul A. Wilson(GlaxoSmithKline (United Kingdom)), Gaelle A. Douillard Guilloux(GlaxoSmithKline (France)), William E. Wixted(GlaxoSmithKline (United Kingdom)), Klio Maratou(Age UK), Kitty Moores(GlaxoSmithKline (United Kingdom)), Stephen Hughes(GlaxoSmithKline (United Kingdom)), Timothy W. Gant(Medical Research Council), Linda C. Warnock(GlaxoSmithKline (United Kingdom)), Gemma Turner(GlaxoSmithKline (United Kingdom)), Emma Koppe(GlaxoSmithKline (United Kingdom)), Jeremy Kitson(GlaxoSmithKline (United Kingdom)), Sofie Eriksson(GlaxoSmithKline (United Kingdom))
Cited by 109
Related Papers
Characterization of the human patatin-like phospholipase family
|Journal of Lipid Research|2006|302
Doxorubicin In Vivo Rapidly Alters Expression and Translation of Myocardial Electron Transport Chain Genes, Leads to ATP Loss and Caspase 3 Activation
|PLoS ONE|2010|127
Assessing unintended hybridization-induced biological effects of oligonucleotides
|Nature Biotechnology|2012|108
Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses
|Advanced Drug Delivery Reviews|2014|91
Strategies for In Vivo Screening and Mitigation of Hepatotoxicity Associated with Antisense Drugs
|Molecular Therapy — Nucleic Acids|2017|62